$55.37 +0.42 (%) Merck & Co Inc - NYSE

Aug. 28, 2015 | 04:00 PM

Partner Headlines

  1. Kyle Bass Focuses on Fuel, Pharmaceutical Stocks in Second Quarter

    GuruFocus | Aug. 24, 2015 | 19:15PM EST
  2. New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN and the TECOS Cardiovascular Safety Trial of JANUVIA Will Be Presented at the European Society of Cardiology Congress

    Benzinga | Aug. 20, 2015 | 08:31AM EST
  3. FDA Accepts Supplemental Biologics License Application for KEYTRUDA, Merck's Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review

    Benzinga | Aug. 18, 2015 | 08:03AM EST
  4. Charles Brandes Beefs Up Second-Most Valuable Stake in Portfolio

    GuruFocus | Aug. 14, 2015 | 17:43PM EST
  5. Vanguard Health Care Fund Buys Two New Stakes in Second Quarter

    GuruFocus | Aug. 6, 2015 | 18:14PM EST
  6. Kahn Brothers Reduces Stake in Old Republic International

    GuruFocus | Aug. 5, 2015 | 18:48PM EST
  7. Merck Reports Strong Second Quarter 2015 Earnings with Improved Outlook for the Full Year

    GuruFocus | Jul. 31, 2015 | 15:42PM EST
  8. Amgen Stock Hits High As Street Eyes Growth Drivers

    IBD | Jul. 31, 2015 | 11:20AM EST
  9. Stocks Open Mixed, Dow Lags; Expedia, Amgen, NewLink Rising

    IBD | Jul. 31, 2015 | 10:37AM EST
  10. Amgen, Alexion Q2 Earnings Beat, But Guidance Differs

    IBD | Jul. 30, 2015 | 18:49PM EST
  11. Big pharmas beat Q2 views

    IBD | Jul. 28, 2015 | 18:42PM EST
  12. Gilead Q2 Earnings Soar As HCV Shines, HIV Rebounds

    IBD | Jul. 28, 2015 | 16:34PM EST
  13. Pfizer, Merck Beat Q2 Views; Sanofi Makes PD-1 Deal

    IBD | Jul. 28, 2015 | 13:03PM EST
  14. U.S. Equity Futures Climb, Fed in Focus

    FoxBusiness | Jul. 28, 2015 | 08:00AM EST
  15. Merck Q2 Profit Beats Estimates

    Benzinga | Jul. 28, 2015 | 07:43AM EST
  16. European Commission Approves MSD's Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), for Both First-line and Previously-treated Patients with Advanced Melanoma

    Benzinga | Jul. 22, 2015 | 07:00AM EST
  17. It's Not Too Late To Buy Gilead Sciences

    GuruFocus | Jul. 17, 2015 | 12:01PM EST
  18. Manning & Napier Advisors' Most Weighted Trades in Q2 2015

    GuruFocus | Jul. 10, 2015 | 16:32PM EST
  19. Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint

    Benzinga | Jun. 29, 2015 | 08:31AM EST
  20. Intrexon Corp is expanding his business

    GuruFocus | Jun. 25, 2015 | 12:54PM EST
  21. Just How Big Can Leaders Skyworks, Valeant Grow In Market Cap?

    IBD | Jun. 22, 2015 | 18:52PM EST
  22. Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story

    GuruFocus | Jun. 22, 2015 | 18:34PM EST
  23. Where Can Mega-Drug Stock Gilead Sciences Go Now?

    IBD | Jun. 22, 2015 | 13:56PM EST
  24. Stocks Jump At The Starting Bell; Macom And Paycom Head IBD 50 Stocks

    IBD | Jun. 22, 2015 | 10:46AM EST
  25. MERCK's

    IBD | Jun. 17, 2015 | 18:41PM EST
  26. Benzinga's M&A Chatter for Tuesday June 16, 2015

    Benzinga | Jun. 16, 2015 | 18:04PM EST
  27. New Migraine Drugs Could Ease Investors' Headaches

    IBD | Jun. 11, 2015 | 08:02AM EST
  28. TECOS, Merck's Cardiovascular Safety Trial of JANUVIA, Met Primary Endpoint in Patients with Type 2 Diabetes

    Benzinga | Jun. 10, 2015 | 07:02AM EST
  29. Benzinga's M&A Chatter for Monday June 8, 2015

    Benzinga | Jun. 8, 2015 | 20:17PM EST
  30. TECOS, Merck's Cardiovascular Safety Trial of JANUVIA, Met Primary Endpoint in Patients with Type 2 Diabetes

    Benzinga | Jun. 8, 2015 | 16:30PM EST
  31. Regeneron/Sanofi Cholesterol Drug Under FDA Scrutiny

    IBD | Jun. 5, 2015 | 12:47PM EST
  32. 3 Dividend Leaders That Just Broke Out Of Bases

    IBD | Jun. 4, 2015 | 18:23PM EST
  33. Merck Announces Results from Investigational IMPROVE-IT Study of VYTORIN Published in NEJoM

    Benzinga | Jun. 3, 2015 | 17:00PM EST
  34. Will GlaxoSmithKline Cut Its 6% Dividend?

    GuruFocus | Jun. 3, 2015 | 15:32PM EST
  35. ImmunoGen Surprises, PD-1 Drugs Under Scrutiny At ASCO

    IBD | Jun. 1, 2015 | 17:48PM EST
  36. Bristol Dives On Cancer Drug

    IBD | May. 29, 2015 | 18:43PM EST
  37. Bristol Sinks On Lung Cancer Data; Merck Up On 2 Trials

    IBD | May. 29, 2015 | 16:22PM EST
  38. Merck got EU's CHMP

    IBD | May. 22, 2015 | 18:22PM EST
  39. Endo International Acquires Par Pharmaceuticals For $8 Billion

    GuruFocus | May. 21, 2015 | 10:48AM EST
  40. Puma Crashes, Roche Rises On Cancer Data News

    IBD | May. 14, 2015 | 12:59PM EST
  41. Intrexon

    IBD | May. 11, 2015 | 18:46PM EST
  42. MERCK

    IBD | May. 11, 2015 | 18:46PM EST
  43. Merck's Stock Price, Dividend Yield Beating S&P 500

    IBD | May. 6, 2015 | 18:13PM EST
  44. Vanguard Adds to Four of Its Largest Stakes

    GuruFocus | May. 4, 2015 | 19:24PM EST
  45. Biogen Making A Breakthrough In Treating Alzheimer's

    GuruFocus | May. 2, 2015 | 16:04PM EST
  46. Big Pharma Beats Wall St.

    IBD | Apr. 28, 2015 | 19:11PM EST
  47. Merck Jumps, United Therapeutics Drops On Q1 Earnings

    IBD | Apr. 28, 2015 | 18:50PM EST
  48. Stocks Recover Off Lows, End Mixed; Twitter Crashes

    IBD | Apr. 28, 2015 | 16:16PM EST
  49. Stocks Recover After Volatile Start; Merck Props Up Dow

    IBD | Apr. 28, 2015 | 14:47PM EST
  50. Merck Up On Q1, Januvia Report; Bristol, Pfizer Mixed

    IBD | Apr. 28, 2015 | 12:47PM EST
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!